Davalintide

Davalintide is an Amylin -mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC50 = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC50 = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes[1][2].

863919-85-1

12352209

Amylin Receptor; CGRP Receptor

GPCR/G Protein; Neuronal Signaling

Metabolism-protein/nucleotide metabolism

Metabolic Disease

OC(C=C1)=CC=C1C[C@H](NC([C@H]([C@H](O)C)NC([C@H](CCC(N)=O)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CC(C)C)NC([C@H](CCC(O)=O)NC([C@H](CCC(N)=O)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC(CNC([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@H]2NC([C@](NC([C@@H](NC([C@](NC([C@@H](NC([C@H](CSSC2)NC([C@@H](N)CCCCN)=O)=O)CC(N)=O)=O)([H])[C@H](O)C)=O)C)=O)([H])[C@H](O)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC3=CN=CN3)=O)=O)=O)=O)=O)C(N4[C@@H](CCC4)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(N)=O)C(N[C@@H]([C@H](O)C)C(NCC(N[C@@H](CO)C(N[C@@H](CC(N)=O)C(N[C@@H]([C@H](O)C)C(N[C@H](C(N)=O)CC5=CC=C(C=C5)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

C152H248N50O49S2

3624.03

[1]Mack CM, et al. Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide. Diabetes Obes Metab. 2011 Dec;13 (12) :1105-13. |[2]Mack CM, et al. Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int J Obes (Lond) . 2010 Feb;34 (2) :385-95.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11320/

Peptides

No Development Reported